Matches in SemOpenAlex for { <https://semopenalex.org/work/W1990309105> ?p ?o ?g. }
- W1990309105 endingPage "77" @default.
- W1990309105 startingPage "61" @default.
- W1990309105 abstract "Neurofibromatosis type 2 (NF2) is a tumor suppressor gene syndrome characterized by multiple schwannomas, especially vestibular schwannomas (VS), and meningiomas. Anticancer drug trials are now being explored, but there are no standardized endpoints in NF2. We review the challenges of NF2 clinical trials and suggest possible response criteria for use in initial phase II studies. We suggest two main response criteria in such trials. Objective radiographic response is defined as a durable 20% or greater reduction in VS volume based on post-contrast T1-weighted MRI images collected with 3 mm or finer cuts through the internal auditory canal. Hearing response is defined as a statistically significant improvement in word recognition scores using 50-word recorded lists in audiology. A possible composite endpoint incorporating both radiographic response and hearing response is outlined. We emphasize pitfalls in response assessment and suggest guidelines to minimize misinterpretations of response. We also identify research goals in NF2 to facilitate future trial conduct, such as identifying the expectations for time to tumor progression and time to measurable hearing loss in untreated NF2-related VS, and the relation of both endpoints to patient prognostic factors (such as age, baseline tumor volume, and measures of disease severity). These data would facilitate future use of endpoints based on stability of tumor size and hearing, which might be more appropriate for testing certain drugs. We encourage adoption of standardized endpoints early in the development of phase II trials for this population to facilitate comparison of results across trials of different agents." @default.
- W1990309105 created "2016-06-24" @default.
- W1990309105 creator A5001528733 @default.
- W1990309105 creator A5004250524 @default.
- W1990309105 creator A5005580627 @default.
- W1990309105 creator A5006079064 @default.
- W1990309105 creator A5015043044 @default.
- W1990309105 creator A5026837154 @default.
- W1990309105 creator A5031920574 @default.
- W1990309105 creator A5038428624 @default.
- W1990309105 creator A5051168746 @default.
- W1990309105 creator A5051287778 @default.
- W1990309105 creator A5059797681 @default.
- W1990309105 date "2009-05-01" @default.
- W1990309105 modified "2023-10-15" @default.
- W1990309105 title "Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma" @default.
- W1990309105 cites W1486901783 @default.
- W1990309105 cites W1518686938 @default.
- W1990309105 cites W1570423803 @default.
- W1990309105 cites W1578041646 @default.
- W1990309105 cites W1703719788 @default.
- W1990309105 cites W172492937 @default.
- W1990309105 cites W1903099878 @default.
- W1990309105 cites W1959628099 @default.
- W1990309105 cites W1966823131 @default.
- W1990309105 cites W1968208476 @default.
- W1990309105 cites W1968287404 @default.
- W1990309105 cites W1969961802 @default.
- W1990309105 cites W1970106556 @default.
- W1990309105 cites W1971563829 @default.
- W1990309105 cites W1971822577 @default.
- W1990309105 cites W1973106770 @default.
- W1990309105 cites W1974062930 @default.
- W1990309105 cites W1976036004 @default.
- W1990309105 cites W1983247861 @default.
- W1990309105 cites W1985968080 @default.
- W1990309105 cites W1986556404 @default.
- W1990309105 cites W1989314007 @default.
- W1990309105 cites W1991120583 @default.
- W1990309105 cites W1991628608 @default.
- W1990309105 cites W1992342043 @default.
- W1990309105 cites W1992812368 @default.
- W1990309105 cites W1994946167 @default.
- W1990309105 cites W1996009245 @default.
- W1990309105 cites W1999205504 @default.
- W1990309105 cites W2001355942 @default.
- W1990309105 cites W2002736748 @default.
- W1990309105 cites W2006442688 @default.
- W1990309105 cites W2007143551 @default.
- W1990309105 cites W2007559871 @default.
- W1990309105 cites W2007831493 @default.
- W1990309105 cites W2008848053 @default.
- W1990309105 cites W2010793999 @default.
- W1990309105 cites W2012548211 @default.
- W1990309105 cites W2015373739 @default.
- W1990309105 cites W2016266603 @default.
- W1990309105 cites W2018146387 @default.
- W1990309105 cites W2018161909 @default.
- W1990309105 cites W2020990826 @default.
- W1990309105 cites W2022428580 @default.
- W1990309105 cites W2022510743 @default.
- W1990309105 cites W2023247590 @default.
- W1990309105 cites W2023923385 @default.
- W1990309105 cites W2025783519 @default.
- W1990309105 cites W2027587957 @default.
- W1990309105 cites W2027750478 @default.
- W1990309105 cites W2027928618 @default.
- W1990309105 cites W2028675530 @default.
- W1990309105 cites W2029133561 @default.
- W1990309105 cites W2037622214 @default.
- W1990309105 cites W2042567095 @default.
- W1990309105 cites W2043296887 @default.
- W1990309105 cites W2044421162 @default.
- W1990309105 cites W2045399397 @default.
- W1990309105 cites W2045548422 @default.
- W1990309105 cites W2046364630 @default.
- W1990309105 cites W2048661494 @default.
- W1990309105 cites W2048977508 @default.
- W1990309105 cites W2049205854 @default.
- W1990309105 cites W2053537126 @default.
- W1990309105 cites W2056663828 @default.
- W1990309105 cites W2056950677 @default.
- W1990309105 cites W2057186316 @default.
- W1990309105 cites W2058832465 @default.
- W1990309105 cites W2059635690 @default.
- W1990309105 cites W2060071297 @default.
- W1990309105 cites W2063661856 @default.
- W1990309105 cites W2064505938 @default.
- W1990309105 cites W2067158021 @default.
- W1990309105 cites W2068344889 @default.
- W1990309105 cites W2071401387 @default.
- W1990309105 cites W2075598775 @default.
- W1990309105 cites W2080805836 @default.
- W1990309105 cites W2086610618 @default.
- W1990309105 cites W2087502377 @default.
- W1990309105 cites W2090407171 @default.
- W1990309105 cites W2090905447 @default.
- W1990309105 cites W2092264755 @default.